Newsroom

Sorted by: Latest
-

Pernod Ricard : déclaration des droits de vote - novembre 2025

PARIS--(BUSINESS WIRE)--Regulatory News: Pernod Ricard (Paris:RI): En application des articles 221-1 et 223-16 du Règlement Général de l'AMF, les émetteurs publient par communiqué et sur leur site Internet, le nombre total de droits de vote et le nombre d'actions composant le capital de la société s'ils ont varié par rapport à ceux publiés antérieurement : Situation au 30.11.2025 1) Nombre total d'actions en circulation composant le capital de la société 252 269 195     2) Nombre total de droit...
-

NFL Biosciences Obtains Complementary Characterization Results for NFL-101, its first-in-class Drug Candidate for Smoking Cessation, and Prepares a New Patent Application

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL Biosciences SA (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addiction, announces that it has obtained the expected results from the extended characterization program of NFL-101, in accordance with the guidance provided by several European regulatory agencies and the U.S. FDA. These results strengthen intellectual property by consolidating undisclos...
-

Mobile Virtual Network Operator (MVNO) Services Markets to 2029: Market to grow by Over $20 Billion, Driven by Rising Telecom Adoption, Increasing Mobile Data Demand, and Advancements in VAS - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Mobile Virtual Network Operator (MVNO) Services Market 2025-2029" report has been added to ResearchAndMarkets.com's offering. The mobile virtual network operator (MVNO) services market is forecasted to grow by USD 20.8 billion during 2024-2029, accelerating at a CAGR of 10% The report on the mobile virtual network operator (MVNO) services market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysi...
-

Verimatrix : Signature d'un accord pour la cession des actifs Extended Threat Defense (protection des applications mobiles) à Guardsquare

AIX-EN-PROVENCE, France & SAN DIEGO--(BUSINESS WIRE)--Regulatory News : VERIMATRIX (Euronext Paris : VMX, FR0010291245), l'un des principaux fournisseurs de solutions de sécurité utilisateur pour un monde connecté plus sûr, annonce la signature d'un accord avec la société belge Guardsquare, leader dans le domaine de la sécurité des applications mobiles, pour la vente de ses actifs Extended Threat Defense (XTD). Guardsquare, créateur de l'outil d'optimisation open source ProGuard, propose la pla...
-

Verimatrix: Signing of an Agreement for the Sale of XTD Assets (Code and Application Protection) to Guardsquare

AIX-EN-PROVENCE, France & SAN DIEGO--(BUSINESS WIRE)--Regulatory News: VERIMATRIX (Euronext Paris: VMX, FR0010291245), a leading provider of user security solutions for a safer connected world, announces the signing of an agreement with Belgium-based Guardsquare, the leading provider of mobile application security, for the sale of its Extended Threat Defense (XTD) assets. Guardsquare, the creators of the open-source optimization tool, ProGuard, offers the most complete mobile application securi...
-

Eurofins: Weekly Report on Share Repurchases From 01st December to 05th December 2025

LUXEMBOURG--(BUSINESS WIRE)--Regulatory News: Eurofins (Paris:ERF): Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code) EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/01/2025 FR0014000MR3 20 000 58.9527 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/02/2025 FR0014000MR3 20 000 59.3808 XPAR EUROFINS SCIENTIFIC 529900JEHFM47DYY3S57 12/0...
-

Median Technologies Partners With Leading U.S. Healthcare Company to Bring eyonis® LCS to Patients Across the U.S. and Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”), manufacturer of eyonis® , a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced the signing of a non-exclusive global commercial distribution agreement...
-

Median Technologies s’associe à un leader américain de la Santé pour mettre son logiciel dispositif médical eyonis® LCS à disposition des patients aux États-Unis et en Europe

SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News: Median Technologies (FR0011049824, ALMDT, éligible PEA/PME, « Median » ou « La Société »), fabricant d’eyonis®, une suite de logiciels dispositifs médicaux basés sur l’intelligence artificielle (IA) pour le diagnostic précoce des cancers, et un leader mondial de la fourniture d’analyses d’images par IA et de services centraux d’imagerie pour les essais cliniques en oncologie de l’industrie biopharmaceutique, annonce aujourd’hui la sign...
-

NFL Biosciences obtient des résultats de caractérisation complémentaires de NFL-101, candidat-médicament first-in-class dans l’indication du sevrage tabagique et prépare une nouvelle demande de brevet

MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), société biopharmaceutique développant des médicaments botaniques innovants pour le traitement des addictions, annonce avoir obtenu les résultats attendus dans le cadre du programme de caractérisation approfondie de NFL-101, conformément aux conseils formulés par plusieurs agences réglementaires européennes et par la FDA américaine, ainsi que les partenaires pharmaceutiques pote...
-

Bank of New York Mellon UK Regulatory Announcement: FRN Variable Rate Fix

LONDON--(BUSINESS WIRE)--  As Agent Bank, please be advised of the following rate determined on: 12/8/2025 Issue ¦ Barclaycard Funding PLC 15 - 1 GBP 1,764,706,000 FRN due November 2023     ISIN Number ¦ GB009A2Y8IO2 ISIN Reference ¦ 009A2Y8IO Issue Nomin GBP ¦ 1764706000 Period ¦ 11/17/2025 to 12/15/2025   Payment Date 12/15/2025 Number of Days ¦ 28 Rate ¦ 5.3207   Denomination GBP ¦ 1000   ¦ 1764706000   ¦       Amount Payable per Denomination ¦ 4.08   ¦ 7202882.03   ¦       Bank of New York...